Search - tctmd.com

Displaying 161 - 180 of 186

Sort: Relevancy | Date

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Industry News

Corvia Medical Completes Randomization In Reduce Lap-Hf II Pivotal Trial And Gains Fda Authorization To Provide Continued Access For The Corvia Atrial Shunt

November 17, 2020

News Daily News

Heart Failure Doubles Risk of Dying From COVID-19

L.A. McKeown

October 30, 2020

News Conference News HFSA 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

L.A. McKeown

October 12, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

Shelley Wood

October 01, 2020

News Daily News

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

Shelley Wood

September 22, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Daily News

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

Shelley Wood

February 26, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Shelley Wood

November 22, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Digging In: Adherence to Plant-Based Diets Linked to Fewer HF Hospitalizations

L.A. McKeown

April 23, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Daily News

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Shelley Wood

February 26, 2019

News Industry News

Corvia Medical Announces Strong Positive One-Year Data From Reduce LAP-HF I Randomized, Sham-Controlled Clinical Trial

August 27, 2018

Advertisement

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Corvia Medical Completes Randomization In Reduce Lap-Hf II Pivotal Trial And Gains Fda Authorization To Provide Continued Access For The Corvia Atrial Shunt

Heart Failure Doubles Risk of Dying From COVID-19

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

TCTMD’s Top 10 Most Popular Stories for September 2020

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

TCTMD’s Top 10 Most Popular Stories for September 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Digging In: Adherence to Plant-Based Diets Linked to Fewer HF Hospitalizations

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Corvia Medical Announces Strong Positive One-Year Data From Reduce LAP-HF I Randomized, Sham-Controlled Clinical Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content